TrialBritish journal of cancer2012

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma.

C M M Prado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.